Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Beta This is a new resource - your feedback will help us improve it.

Series: Audit of Medicaid Fee-for-Service Payments for Drug Testing Services

Announced on  | Last Modified on  | Series Number: SRS-A-27-005

OBJECTIVE

Laboratory services are a mandatory Medicaid benefit under Federal law and regulations. Federal regulations require laboratory services to be ordered by a physician or other practitioner and performed by a Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified laboratory (42 CFR 440.30 (a) and (c)). Drug testing is the process of using a biological sample (e.g., urine or blood) to detect the presence or absence of a drug or its metabolites in the body. Generally, there are two types of drug testing services: presumptive and definitive. Definitive drug testing is used when greater analytical specificity is necessary and has a higher reimbursement rate than presumptive drug testing, which simply indicates a presence or absence of the drug or its metabolite in the body. Laboratories bill for definitive drug testing based on the number of drug classes being tested. Prior OIG audits and CMS reports have identified risks of overpayments for the highest definitive drug testing code (procedure code G0483) in Medicare. We will review whether selected States’ Medicaid fee-for-service payments to laboratories for definitive drug testing services complied with Federal and State requirements.

There is 1 project in this series.

ACTIVE PROJECTS IN THIS SERIES (1)

Audit of Medicaid Fee-for-Service Payments for Drug Testing Services

TIMELINE

  • November 5, 2026
    Series Number SRS-A-27-005 Assigned
  • November 5, 2026
    Project Announced

    Audit of Medicaid Fee-for-Service Payments for Drug Testing Services - OAS-26-09-080

  • Today
    1 Audit In-Progress
  • Est FY2028
    Estimated Fiscal Year for Series Completion

-